https://www.hcplive.com/view/pangenotypic-daa-therapy-safe-effective-in-children-with-hcv-study-finds
0
0
11/30/23 at 4:04pm
Organization
Hcplive.com
35 words
0
Comments
8 weeks of treatment with glecaprevir/pibrentasvir was found to be safe and effective among patients with HCV aged 3-17 years.
You are the first to view
Create an account
or login to join the discussion